BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 27734030)

  • 1. LIM kinase/cofilin dysregulation promotes macrothrombocytopenia in severe von Willebrand disease-type 2B.
    Kauskot A; Poirault-Chassac S; Adam F; Muczynski V; Aymé G; Casari C; Bordet JC; Soukaseum C; Rothschild C; Proulle V; Pietrzyk-Nivau A; Berrou E; Christophe OD; Rosa JP; Lenting PJ; Bryckaert M; Denis CV; Baruch D
    JCI Insight; 2016 Oct; 1(16):e88643. PubMed ID: 27734030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein kinase C signaling dysfunction in von Willebrand disease (p.V1316M) type 2B platelets.
    Casari C; Paul DS; Susen S; Lavenu-Bombled C; Harroche A; Piatt R; Poe KO; Lee RH; Bryckaert M; Christophe OD; Lenting PJ; Denis CV; Bergmeier W
    Blood Adv; 2018 Jun; 2(12):1417-1428. PubMed ID: 29925524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. von Willebrand factor mutation promotes thrombocytopathy by inhibiting integrin αIIbβ3.
    Casari C; Berrou E; Lebret M; Adam F; Kauskot A; Bobe R; Desconclois C; Fressinaud E; Christophe OD; Lenting PJ; Rosa JP; Denis CV; Bryckaert M
    J Clin Invest; 2013 Dec; 123(12):5071-81. PubMed ID: 24270421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of aberrant von Willebrand factor-GPIbα interaction on megakaryopoiesis and platelets in humanized type 2B von Willebrand disease model mouse.
    Kanaji S; Morodomi Y; Weiler H; Zarpellon A; Montgomery RR; Ruggeri ZM; Kanaji T
    Haematologica; 2022 Sep; 107(9):2133-2143. PubMed ID: 35142156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A genetically-engineered von Willebrand disease type 2B mouse model displays defects in hemostasis and inflammation.
    Adam F; Casari C; Prévost N; Kauskot A; Loubière C; Legendre P; Repérant C; Baruch D; Rosa JP; Bryckaert M; de Groot PG; Christophe OD; Lenting PJ; Denis CV
    Sci Rep; 2016 May; 6():26306. PubMed ID: 27212476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relevance of platelet desialylation and thrombocytopenia in type 2B von Willebrand disease: preclinical and clinical evidence.
    Dupont A; Soukaseum C; Cheptou M; Adam F; Nipoti T; Lourenco-Rodrigues MD; Legendre P; Proulle V; Rauch A; Kawecki C; Bryckaert M; Rosa JP; Paris C; Ternisien C; Boisseau P; Goudemand J; Borgel D; Lasne D; Maurice P; Lenting PJ; Denis CV; Susen S; Kauskot A
    Haematologica; 2019 Dec; 104(12):2493-2500. PubMed ID: 30819911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutation-specific hemostatic variability in mice expressing common type 2B von Willebrand disease substitutions.
    Golder M; Pruss CM; Hegadorn C; Mewburn J; Laverty K; Sponagle K; Lillicrap D
    Blood; 2010 Jun; 115(23):4862-9. PubMed ID: 20371742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apoptotic Platelet Events Are Not Observed in Severe von Willebrand Disease-Type 2B Mutation p.V1316M.
    Berrou E; Kauskot A; Adam F; Harel A; Legendre P; Lavenu Bombled C; Rothschild C; Prevost N; Christophe OD; Lenting PJ; Denis CV; Rosa JP; Bryckaert M
    PLoS One; 2015; 10(12):e0143896. PubMed ID: 26645283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accelerated uptake of VWF/platelet complexes in macrophages contributes to VWD type 2B-associated thrombocytopenia.
    Casari C; Du V; Wu YP; Kauskot A; de Groot PG; Christophe OD; Denis CV; de Laat B; Lenting PJ
    Blood; 2013 Oct; 122(16):2893-902. PubMed ID: 23945153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutation and ADAMTS13-dependent modulation of disease severity in a mouse model for von Willebrand disease type 2B.
    Rayes J; Hollestelle MJ; Legendre P; Marx I; de Groot PG; Christophe OD; Lenting PJ; Denis CV
    Blood; 2010 Jun; 115(23):4870-7. PubMed ID: 20200350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel platelet-type von Willebrand disease mutation (GP1BA p.Met255Ile) associated with type 2B "Malmö/New York" von Willebrand disease.
    Lavenu-Bombled C; Guitton C; Dupuis A; Baas MJ; Desconclois C; Dreyfus M; Li R; Caron C; Gachet C; Fressinaud E; Lanza F
    Thromb Haemost; 2016 Nov; 116(6):1070-1078. PubMed ID: 27683759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Type 2B von Willebrand disease mutations differentially perturb autoinhibition of the A1 domain.
    Legan ER; Liu Y; Arce NA; Parker ET; Lollar P; Zhang XF; Li R
    Blood; 2023 Mar; 141(10):1221-1232. PubMed ID: 36580664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Laboratory diagnosis and molecular classification of von Willebrand disease.
    Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
    Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenotypic identification of platelet-type von Willebrand disease and its discrimination from type 2B von Willebrand disease: a question of 2B or not 2B? A story of nonidentical twins? Or two sides of a multidenominational or multifaceted primary-hemostasis coin?
    Favaloro EJ
    Semin Thromb Hemost; 2008 Feb; 34(1):113-27. PubMed ID: 18393148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A family having type 2B von Willebrand disease with an R1306W mutation: Severe thrombocytopenia leads to the normalization of high molecular weight multimers.
    Ozeki M; Kunishima S; Kasahara K; Funato M; Teramoto T; Kaneko H; Fukao T; Kondo N
    Thromb Res; 2010 Feb; 125(2):e17-22. PubMed ID: 19740526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet-type von Willebrand disease: a rare, often misdiagnosed and underdiagnosed bleeding disorder.
    Othman M
    Semin Thromb Hemost; 2011 Jul; 37(5):464-9. PubMed ID: 22102188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet activation and aggregation induced by recombinant von Willebrand factors reproducing four type 2B von Willebrand disease missense mutations.
    de Romeuf C; Hilbert L; Mazurier C
    Thromb Haemost; 1998 Jan; 79(1):211-6. PubMed ID: 9459349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. von Willebrand disease type 2A phenotypes IIC, IID and IIE: A day in the life of shear-stressed mutant von Willebrand factor.
    Brehm MA; Huck V; Aponte-Santamaría C; Obser T; Grässle S; Oyen F; Budde U; Schneppenheim S; Baldauf C; Gräter F; Schneider SW; Schneppenheim R
    Thromb Haemost; 2014 Jul; 112(1):96-108. PubMed ID: 24598842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease.
    Jilma B; Paulinska P; Jilma-Stohlawetz P; Gilbert JC; Hutabarat R; Knöbl P
    Thromb Haemost; 2010 Sep; 104(3):563-70. PubMed ID: 20589313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic Differentiation of von Willebrand Disease Types 1 and 2 by von Willebrand Factor Multimer Analysis and DDAVP Challenge Test.
    Michiels JJ; Smejkal P; Penka M; Batorova A; Pricangova T; Budde U; Vangenechten I; Gadisseur A
    Clin Appl Thromb Hemost; 2017 Sep; 23(6):518-531. PubMed ID: 27443694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.